North America Associated Press
New Ionis Data Supports Olezarsen as Potential Treatment for Severe Hypertriglyceridemia
Ionis Pharmaceuticals to present new analyses supporting olezarsen for severe hypertriglyceridemia at upcoming congresses.
Ionis Pharmaceuticals is set to present new data from pivotal studies CORE and CORE2 supporting the use of olezarsen for treating severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the blood. The company will present these findings at upcoming congresses.
Brief written with AI from reporting by Associated Press. All rights to the original story belong to the publisher.